Subtype
Malignant Male Reproductive System Neoplasm
CI-CAN-00003180Explore in graph →
1,451 active trials27 approved drugs58 evidence items
- NCIt
- C8561
Loading cancer entity…
Subtype
CI-CAN-00003180Explore in graph →
Clinical trials
6,227 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (762)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01816048 | NaF Positron Emission Tomography/Computed Tomography (PET/CT)Imaging to Assess Treatment Responsiveness to TAK-700 in Patients With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastasis | terminated | Phase 2 | 8 | University of Wisconsin, MadisonOTHER | 1 | Dec 9, 2019 | clinicaltrials |
| NCT00444639 | Study to Assess the Non-inferiority of Pamorelin® 11,25mg SC Injected Versus Pamorelin® 11,25mg IM Injected in Patients Suffering From Advanced Prostate Cancer (PAMOJECT) | terminated | Phase 2 | 25 | IpsenINDUSTRY | 1 |
| Nov 22, 2019 |
| clinicaltrials |
| NCT01119118 | ZD4054 With Positron Emission Tomography/Magnetic Resonance Imaging (PET/MRI) for Prostate Cancer | terminated | Phase 2 | 6 | University of Wisconsin, MadisonOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT01533753 | Quality of Life Study Using Gabapentin Versus Venlafaxine in Treating Hot Flashes in Patients With Prostate Cancer | terminated | Phase 2 | 5 | University of Wisconsin, MadisonOTHER | 1 | Nov 21, 2019 | clinicaltrials |
| NCT02758132 | Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases | terminated | Phase 2 | 1 | University of HawaiiOTHER | 1 | Nov 8, 2019 | clinicaltrials |
| NCT01562522 | Evaluation of the Effect of Psycho-oncological Intervention on Well-being of Patients With Advanced Prostate Cancer on LHRH Analogs and Their Partners. A Randomized Controlled Pilot Study.(EXPEDIENT) | terminated | Phase 2 | 6 | IpsenINDUSTRY | 1 | Nov 7, 2019 | clinicaltrials |
| NCT01253642 | Phenelzine Sulfate and Docetaxel in Treating Patients With Prostate Cancer With Progressive Disease After First-Line Therapy With Docetaxel | terminated | Phase 2 | 11 | OHSU Knight Cancer InstituteOTHER | 1 | Oct 2, 2019 | clinicaltrials |
| NCT01374087 | Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer(ANABRAQ) | terminated | Phase 2 | 32 | IpsenINDUSTRY | 1 | Sep 18, 2019 | clinicaltrials |
| NCT02710422 | Miami Membrane for Potency (MMEP) Trial(MMEP) | terminated | Phase 2 | 24 | University of MiamiOTHER | 1 | Sep 11, 2019 | clinicaltrials |
| NCT01126879 | Genistein in Treating Patients With Prostate Cancer | terminated | Phase 2 | 12 | Northwestern UniversityOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Jun 18, 2019 | clinicaltrials |
| NCT00996502 | Study of Bevacizumab and Erlotinib for Patients With Hormone Refractory Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Columbia UniversityOTHER | 1 | Mar 27, 2019 | clinicaltrials |
| NCT01994590 | Dovitinib (TKI258) and Abiraterone Acetate in Metastatic Castrate-Resistant Prostate Cancer (mCRPC) | terminated | Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2019 | clinicaltrials |
| NCT01163084 | Leuprolide Acetate or Goserelin Acetate With or Without Vismodegib Followed by Surgery in Treating Patients With Locally Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2019 | clinicaltrials |
| NCT02459912 | Unilateral Nerve-Sparing Cryoablation for Low-Risk, Clinically Localized, Unilateral Prostate Cancer(POTENT-C) | terminated | Phase 2 | 1 | NYU Langone HealthOTHER | 1 | Feb 6, 2019 | clinicaltrials |
| NCT00924807 | Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Beth Israel Medical CenterOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT00526591 | Everolimus in Treating Patients With Newly Diagnosed Localized Prostate Cancer | terminated | Phase 2 | 17 | Jorge A. Garcia, MDOTHER | 1 | Dec 6, 2018 | clinicaltrials |
| NCT01703065 | Cabozantinib in Men With Castration-Resistant Prostate Cancer | terminated | Phase 2 | 9 | University of WashingtonOTHER | 1 | Dec 4, 2018 | clinicaltrials |
| NCT02494713 | Hormonal Therapy and Chemotherapy Followed by Prostatectomy in Patients With Prostate Cancer | terminated | Phase 2 | 4 | The University of Texas Health Science Center, HoustonOTHER | 1 | Nov 27, 2018 | clinicaltrials |
| NCT00103376 | Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer | terminated | Phase 2 | 23 | Medical University of South CarolinaOTHER | 1 | Nov 5, 2018 | clinicaltrials |
| NCT00080782 | Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases | terminated | Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT01354951 | Assessing the Potential for Reduced Toxicity Using Focal Brachytherapy in Early Stage, Low Volume Prostate Cancer | terminated | Phase 2 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Oct 19, 2018 | clinicaltrials |
| NCT00670046 | Valproic Acid in Treating Patients With Progressive, Non-Metastatic Prostate Cancer | terminated | Phase 2 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 28, 2018 | clinicaltrials |
| NCT00953576 | Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer(KHLAD) | terminated | Phase 1 / Phase 2 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2018 | clinicaltrials |
| NCT00527124 | Docetaxel and Prednisone With or Without Cediranib in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2018 | clinicaltrials |
| NCT01439542 | FASTR: Fairly Brief Androgen Suppression and Stereotactic Radiotherapy for High Risk Prostate Cancer(FASTR) | terminated | Phase 2 | 19 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sOTHER | 1 | Aug 9, 2018 | clinicaltrials |
| NCT01335204 | Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Medical University of South CarolinaOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT00634582 | Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases | terminated | Phase 2 | 2 | Wake Forest University Health SciencesOTHER | 1 | Jul 6, 2018 | clinicaltrials |
| NCT00058448 | S0224, Docetaxel in Treating Patients With Locally Advanced or Metastatic Penile Cancer (TERMINATED) | terminated | Phase 2 | 1 | SWOG Cancer Research NetworkNETWORK | 1 | Jun 28, 2018 | clinicaltrials |
| NCT02215161 | Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 2 | 14 | University of California, San FranciscoOTHER | 1 | Jun 26, 2018 | clinicaltrials |
| NCT01845792 | Study of Abiraterone Acetate and Prednisone in Combination With Cabazitaxel in Patients With Prostate Cancer | terminated | Phase 2 | 7 | University of Colorado, DenverOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT00860158 | Neoadjuvant Dasatinib Plus LHRH Analogue Therapy in High-Risk Localized Prostate Cancer | terminated | Phase 2 | 1 | Noah Hahn, M.D.OTHER | 1 | Mar 14, 2018 | clinicaltrials |
| NCT00638378 | Study of Ruxolitinib (INCB018424) Administered Orally to Patients With Androgen Independent Metastatic Prostate Cancer | terminated | Phase 2 | 22 | Incyte CorporationINDUSTRY | 1 | Feb 12, 2018 | clinicaltrials |
| NCT00003516 | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | terminated | Phase 2 | 16 | Burzynski Research InstituteOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT00003533 | Antineoplaston Therapy in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | 12 | Burzynski Research InstituteOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT00348816 | Docetaxel, Radiation Therapy, and Prednisone in Treating Patients Who Have Undergone Surgery For Prostate Cancer | terminated | Phase 2 | 21 | The University of Texas Health Science Center at San AntonioOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT01200810 | Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Dec 2, 2017 | clinicaltrials |
| NCT00524589 | Calcitriol and Dexamethasone in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy | terminated | Phase 2 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT00480857 | Salvage Radiation Therapy and Taxotere for PSA Failure After Radical Prostatectomy | terminated | Phase 2 | 19 | University of Michigan Rogel Cancer CenterOTHER | 1 | Oct 6, 2017 | clinicaltrials |
| NCT00531687 | Trial of Paclitaxel, Gemcitabine and Cisplatin in Patients With Relapsing Germ Cell Cancer | terminated | Phase 2 | 8 | Rigshospitalet, DenmarkOTHER | 1 | Oct 3, 2017 | clinicaltrials |
| NCT01145508 | Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2017 | clinicaltrials |
| NCT01866423 | Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 2 | 4 | University of Southern CaliforniaOTHER | 1 | Aug 31, 2017 | clinicaltrials |
| NCT03211052 | A Study of Neoadjuvant TAK-700 and Leuprorelin Acetate Followed by Surgery Versus Surgery Alone(NEPTUNE) | terminated | Phase 2 | 16 | Centre of Experimental MedicineOTHER | 1 | Jul 7, 2017 | clinicaltrials |
| NCT00536991 | Calcitriol in Combination With Ketoconazole and Therapeutic Hydrocortisone in Treating Patients With Prostate Cancer | terminated | Phase 1 / Phase 2 | 51 | Roswell Park Cancer InstituteOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00084864 | Calcitriol and Dexamethasone Before Radical Prostatectomy in Treating Patients With Localized Adenocarcinoma (Cancer) of the Prostate | terminated | Phase 2 | 25 | Roswell Park Cancer InstituteOTHER | 1 | Jun 12, 2017 | clinicaltrials |
| NCT01558492 | Carboplatin and Paclitaxel in Patients With Metastatic, Castrate-Resistant Prostate Cancer | terminated | Phase 2 | 3 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 9, 2017 | clinicaltrials |
| NCT01338012 | Sipuleucel-T in Metastatic Castrate Resistant Prostate Cancer(mCRPC) | terminated | Phase 2 | 8 | DendreonINDUSTRY | 1 | Jun 5, 2017 | clinicaltrials |
| NCT00088881 | Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma | terminated | Phase 2 | 62 | National Cancer Institute (NCI)NIH | 1 | May 25, 2017 | clinicaltrials |
| NCT01385293 | BKM120 in Metastatic Castration-resistant Prostate Cancer | terminated | Phase 2 | 30 | Andrew J. Armstrong, MDOTHER | 1 | May 19, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Dec 9, 2019source: clinicaltrials